• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: 3-day vs. 5-day amoxicillin treatment for chest-indrawing pneumonia in children from Malawi

byConstance Wu
August 21, 2020
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Three-day amoxicillin treatment for chest-indrawing pneumonia was not significantly different from five-day amoxicillin treatment in HIV-uninfected children from Malawi.

2. Relapse for pneumonia was not significantly different between treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Bacterial pneumonia is one of the leading causes of death for children under the age of five. Treatment for pneumonia requires appropriate duration of antibacterial therapy to maximizing adherence and minimizing antimicrobial resistance. Currently, the World Health Organization (WHO) recommends administering a five-day course of amoxicillin for chest-indrawing pneumonia defined as cough lasting for less than 14 days or difficulty breathing with visible indrawing of the chest wall. However, it is unclear whether a five-day course is necessary for effective treatment. As such, this study compared the efficacy of three-day amoxicillin treatment to the standard five-day amoxicillin treatment for pneumonia. The study determined patients with the three-day amoxicillin treatment did not have a difference in treatment failure compared to the patients with the five-day amoxicillin treatment. This randomized trial was limited by the lack of laboratory or radiologic testing and the clinical resolution of pneumonia was dependent on the physical exam. Without access to laboratory or radiographic testing, it was unknown if the pneumonia completely resolved or if traces of the infection lingered in the lungs. Nonetheless, this study was strengthened by the high treatment adherence rates and similarly matched treatment groups.

Click to read the study, published today in NEJM

Relevant Reading: Community case management of severe pneumonia with oral amoxicillin in children aged 2-59 months in Haripur district, Pakistan: a cluster randomised trial

In-Depth [randomized controlled trial]: This randomized control trial enrolled 3000 patients in a multicenter study from two sites in Malawi. Children between the ages of 2 to 59 months who presented to the outpatient departments of Kamuzu Central Hospital and Bwaila District Hospital, and met the WHO case definition of chest-indrawing pneumonia were included in this study. The exclusion criteria for the study included children with severe diseases such as malaria, HIV, and anemia. The patients were randomized in a 1:1 ratio to receive either a three-day amoxicillin treatment regimen or a five-day amoxicillin treatment regimen. The primary outcome was treatment failure by the sixth day. Both groups demonstrated high treatment adherence with 91.6% of children receiving all doses in the three-day group and 91.8% of children receiving all doses in the five-day group. There was no significant difference in treatment failure by the sixth day between the three-day amoxicillin treatment group and five-day amoxicillin treatment group (absolute difference, 0.7%; 95% confidence interval [CI], -0.9 to 2.4). Moreover, by the fourteenth day, there was no significant difference in relapse of the infection between the three-day amoxicillin treatment group and the five-day amoxicillin treatment group (absolute difference, 1.0%; 95% CI, -0.8 to 2.9). Finally, 9.8% of children in the three-day group and 8.8% of children in the five-day group experienced at least one serious adverse event from the time of enrollment until the fourteenth day. Specifically, there was one death from pneumonia in the three-day group and two deaths, one from pneumonia and one from gastroenteritis, in the five-day group. Taken together, a three-day amoxicillin regimen was not significantly different for the treatment of chest-indrawing pneumonia compared to the five-day amoxicillin regimen.

RELATED REPORTS

2 Minute Medicine Rewind January 23, 2023

High emergency department pediatric readiness associated with decreased mortality

Intimate partner violence associated with poor socioemotional development in children

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: amoxicillinMalawipediatricspneumonia
Previous Post

No mortality benefit found for hydroxychloroquine or tocilizumab for the treatment of COVID-19

Next Post

Iodine deficiency associated with adverse fetal and gestational outcomes

RelatedReports

Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 30, 2023
Quick Take: Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial
Emergency

High emergency department pediatric readiness associated with decreased mortality

January 16, 2023
Meeting families, demographic information affect child abuse work-up
Pediatrics

Intimate partner violence associated with poor socioemotional development in children

January 5, 2023
2 Minute Medicine Rewind November 23 – November 30, 2014
Emergency

Vaccines for Zaire Ebola virus disease are safe and generate an immune response

January 4, 2023
Next Post
Stochastic resonance stimulation may decrease apnea of prematurity

Iodine deficiency associated with adverse fetal and gestational outcomes

Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Use of drug-coated balloons for treatment of stenotic lesions in arteriovenous fistulas

Cognitive outcomes in older adults undergoing cardiovascular procedures unclear

Evinacumab lowers LDL in homozygous familial hypercholesterolemia patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options